Provectus Biopharmaceuticals
PVCT
PVCT was delisted on the 13th of October, 2016.
39 hedge funds and large institutions have $3.92M invested in Provectus Biopharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 4 closing their positions.
226% more capital inflows, than outflows
Capital inflows: $978K | Capital outflows: $300K
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
30% more funds holding
Funds holding: 30 → 39 (+9)
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
0.39% more ownership
Funds ownership: 2.33% → 2.72% (+0.39%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Virtu KCG Holdings
New York
|
+$442K |
| 2 |
Credit Suisse
Zurich,
Switzerland
|
+$156K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$126K |
| 4 |
Cutter & Co Brokerage
Ballwin,
Missouri
|
+$84.6K |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
+$32.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$254K |
| 2 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$13K |
| 3 |
Carnegie Investment Counsel
Pepper Pike,
Ohio
|
-$10K |
| 4 |
MB Financial Bank - Trust Department
Rosemont,
Illinois
|
-$9.14K |
| 5 |
Private Advisor Group
Morristown,
New Jersey
|
-$6.86K |
PVCT Hedge Fund Activity: Q4 2014 in Review
39 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Provectus Biopharmaceuticals (PVCT) for Q4 2014, worth a combined $3.92M — down 6.4% from $4.19M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new PVCT positions and 4 closed out — a net gain of 5 holders — while 6 added to existing stakes and 5 trimmed.
The largest buyer was Virtu KCG Holdings, adding an estimated $442K. The largest seller was Goldman Sachs, cutting an estimated $254K.
- 39 institutional investors held Provectus Biopharmaceuticals (PVCT) as of Q4 2014, up from 30 in Q3 2014.
- Funds reported $3.92M of Provectus Biopharmaceuticals stock for Q4 2014, down 6.4% quarter-over-quarter.
- 9 funds opened new Provectus Biopharmaceuticals positions in Q4 2014 and 4 closed out, a net change of +5 holders.
- The largest Provectus Biopharmaceuticals buyer in Q4 2014 was Virtu KCG Holdings, an estimated $442K added.
- The largest Provectus Biopharmaceuticals seller in Q4 2014 was Goldman Sachs, an estimated $254K sold.
Based on aggregated 13F filings for Q4 2014.